Key Takeaways Brookfield and family member shareholders of Grifols are in talks to take the Spanish pharmaceutical firm private.The potential buyers asked the board for information so they could ...

Brookfield Asset Management is awaiting information from Grifols SA about related-party transactions as it seeks to complete its due diligence on the business, according to a person familiar with ...

Grifols said its board held an extraordinary meeting over the weekend to study a preliminary offer presented by Brookfield and the Grifols founding family, which holds a stake of around 30% ...

Grifols SA said that its founding family and asset manager Brookfield have made an approach to buy and delist it, after the pharmaceutical producer lost billions in market value amid a short ...

Grifols said it plans to outline its strategy as a standalone company after Brookfield Asset Management dropped out of talks for a $6.82billion takeover bid.

Grifols SA’s board recommended that shareholders reject Brookfield Asset Management’s indicative offer, which values the Spanish drugmaker at €6.45 billion ($6.8 billion).

Grifols faces financial challenges with high debt levels and Brookfield Asset Management in talks to potentially privatize it. See why I rate GRFS stock a Hold.

Shares of Grifols GRFS lost over 7% on Wednesday after the company announced that Canada-based Brookfield Asset Management has withdrawn its plan to acquire it.. Both parties likely failed to ...

Brookfield had filed a non-binding offer on Nov. 19 for Grifols that valued the developer of human plasma-based drugs at 6.45 billion euros ($6.79 billion), which Grifols then said was a ...

Brookfield Asset Management is baring its fangs for fresh blood.. The global investment firm is working with lenders to line up $10.6 billion to acquire Barcelona-based plasma therapeutics company ...